About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
Press releases
Corporate presentation
Scientific Presentations
Scientific Publications
Events and webcasts
Stock information
SEC filings
Financial Statements
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
IR Inquiry
All
2024
2023
2022
2021
2020
2019
02
Feb 2023
17:47 E.S.T.
Cellectis Announces Pricing of Follow-On Offering
Read more
02
Feb 2023
16:19 E.S.T.
Cellectis Announces Launch of Follow-On Offering
Read more
20
Jan 2023
16:30 E.S.T.
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
Read more
17
Jan 2023
07:10 E.S.T.
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
Read more
04
Jan 2023
17:00 E.S.T.
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq
Read more
29
Dec 2022
16:30 E.S.T.
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
Read more
Prev
9
10
11
12
13
Next